3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Advanced Solid Tumor
7
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Melanoma
4
Carcinoma, Hepatocellular
4
Solid Tumor
3
Solid Tumors
2
Lymphoma
2
Head and Neck Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Renal Cell
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Testicular Germ Cell Tumor
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Cancer
1
Interventions
pembrolizumab
2
tislelizumab
1
Trastuzumab
1
Imatinib Mesylate
1
GSK-3326595
1
Cyclophosphamide
1
Blood Specimen Collection
1
BMS-906024
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Adenoid Cystic
×
tislelizumab
×
Clear all
NCT03287427
2023-02-15
MYPHISMO
Peter MacCallum Cancer Centre, Australia
Phase 1
Completed
27 enrolled